- GSK -0.59%
GSK’s Omjjara gains approval in Japan for myelofibrosis treatment
Yahoo Finance · 14 hours ago
Open | 40.47 |
High | 40.48 |
Low | 40.19 |
Mkt Cap | 82.19B |
P/E (TTM) | 14.66 |
Div & Yield | 1.50 & 3.71% |
Prev. Close | 40.55 |
52 Wk. Low | 33.67 |
52 Wk. High | 45.93 |
Related stocks
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 7.36B | 5.90% ▲ |
Net Income | 1.05B | 29.80% ▼ |
Diluted EPS | 1.09 | 30.40% ▼ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $0.99 | - |
Q1 2024 | $0.91 | $1.09 |
Q4 2023 | $0.76 | $0.72 |
S&P 500^GSPC | 5,469.30+21.43 (+0.39%) |
Dow 30^DJI | 39,112.16-299.05 (-0.76%) |
Nasdaq^IXIC | 17,717.65+220.84 (+1.26%) |
11.96+8.63% | |
256.38-0.05% | |
20.52+304.73% |